Stockholm, Sweden, Feb 1, 2024 – The Board of Acarix AB (publ) announces today the appointment of Aamir Mahmood as new CEO with immediate effect, starting today February 1. Mr. Mahmood succeeds Acting CEO Fred Colen as well as Helen Ljungdahl Round who has decided not to return to her position later in 2024.
Aamir Mahmood has more than twenty years of experience in corporate leadership in the medical device industry with a successful track record of Global commercial roles in cardiovascular device markets, including sales, marketing and strategy functions at LivaNova, Boston Scientific, and Merck. Aamir presently serves as General Manager/Vice President Americas of MicroPort CRM, a cardiovascular medical device company with over $200 million sales, formerly part of LivaNova, and acquired by MicroPort Scientific in 2017. MicroPort is an industry leader in the field of pacemakers and other cardiac devices used for diagnosis, treatment and management of heart rhythm disorders and heart failure. Prior to running the Americas for MicroPort, Aamir rotated through two Ex Pat assignments in Europe running Global Sales followed by Global Marketing & Strategy. Aamir has an MBA and is a member of Young Presidents’ Organization (YPO), a global leadership community of extraordinary chief executives.
“It is with great pleasure that the Board of Acarix announces the appointment of Aamir Mahmood as the new CEO to lead this exciting phase of rapid growth, especially in the US. Aamir has an impressive industry track record in the cardiovascular market and brings in strong commercial expertise, leadership and industry network to continue our advancement in the US and global markets. Based in the US, Aamir will lead the Acarix global team to further expand the commercialization efforts, continue to develop the product and indication pipeline, and continue to grow the company to profitability”, says Philip Siberg, Chairman of the Board of Acarix.
“I am honored and excited to embark on a new chapter as CEO of Acarix at an exciting time in the company’s development and focus on driving innovation to truly meet its purpose,” said Mr. Mahmood. “I’m grateful for the opportunity to lead and inspire, driving positive change in the healthcare landscape, while leveraging the recent FDA Approval of the CADScor Systems cutting-edge technology to make a meaningful impact on patients’ lives.”
Aamir succeeds Helen Ljungdahl Round who was appointed CEO of Acarix in January of 2022. The Board wishes to thank Helen for her leadership and accomplishments as CEO of Acarix. Under Helen’s leadership Acarix established a subsidiary and commercial team in the US market, secured key commercial contracts with the Veterans Affairs Health Administration, published a clinical framework for use of the CADScor System in collaboration with the American College of Cardiology (ACC), and raised growth capital from a broad base of investors to enable further market expansion. “As Chairman of the Board, I wish to personally extend my gratitude to Helen, thank her for her hard work and efforts, and have recommended her to the nomination committee of Acarix as a candidate for election as new Board Member of Acarix at the AGM in May 2024”, commented Philip Siberg.
“The last two years working with the Acarix team, the Board, and leading Cardiologists in bringing the CADScor System to the US market has been immensely interesting. I plan to continue to support Acarix and contribute to the success of the CADScor System and its impact on patients and the health care system. I strongly support the appointment of Aamir and am excited to hand over the CEO responsibility to someone with so much experience and drive”, says Helen Ljungdahl Round.
Aamir Mahmood assumes the CEO position on February 1, 2024. The board wishes to thank Fred Colen for the interim leadership of Acarix during the last few months.
As part of the compensation package for Mr. Mahmood, and to secure long-term incentives and commitment from key employees of Acarix, the Board of Acarix will be recommending a new stock options program, and issue a notice to resolve such program at an upcoming extra shareholder’s meeting.
For more information contact:
Philip Siberg, Chairman of the Board, tel +46 70 7906734, philip.siberg@acarix.com